2月10日 - ** Moderna MRNA.O股价在延时交易中下跌 8%，至 39 美元左右
** MRNA称美国食品和药物管理局不会审查其流感疫苗的审批申请 (link)
** 称拒绝审查申请与第 3 阶段前和提交申请前咨询中的反馈意见不一致
** 表示要求与生物制品评估与研究中心会面，以了解拒绝的依据
** 2025 年，MRNA 下降了 29% 以上
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.